Hyderabad-based Suven Pharmaceuticals has suffered a 35.82 per cent fall in bottomline for 2002-03 at Rs 5.26 crore compared with Rs 8.20 crore in the previous fiscal.
Sales rose to Rs 46.96 crore (Rs 42.57 crore). Earnings per share was Rs 11.97 on an equity base of Rs 4.40 crore. The fall in net profit is attributed to changes in product mix in favour of high-volume-low-value products.